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Pentachlorophenol (PCP), hexachlorocyclo-
hexane-α , -β , and -γ (HCH-α , -β , and -γ ),
polychlorinated biphenyls (PCBs), and hexa-
chlorobenzene (HCB) are widely distributed
industrial chemicals. PCBs are used as com-
ponents of mobile oils, elastic sealing
compounds, dielectric fluids in older trans-
formers, heat exchangers, paints and printing
inks, and pesticide extenders and protection
colors for concrete (1–3). The fungicidal
chemicals PCP and HCH were used in wood
preservatives. PCP was banned in Germany
in 1989, and the use of HCH-γ  in pesticides
was strongly reduced since 1991 (4). HCB is
an organochlorine fungicide and is also used
as a softening agent for plastics (5). PCBs are
inert, lipid-soluble molecules and tend to
accumulate in food chains in animals such as
fish (6). PCBs accumulate in the human
body, and their blood levels can be measured
(2,7–10). In cell cultures as well as in animal
experiments, all of these substances were
toxic for lymphocytes in many studies
(11–38), with some notable exceptions
(39–43). Although there are reports of
immunologic dysfunctions in patients with
high exposure to these compounds (44–48),
it is controversial whether the chemicals are
toxic for humans. The compounds occur as
mixtures, and studies on their possible inter-
active effects are therefore important. In pre-
vious studies we demonstrated a suppressive
effect of PCP blood levels of > 10 µg/L on
certain cellular and humoral immune para-
meters (38,49). To avoid an interference of
high PCP levels, we excluded patients with
PCP blood levels > 10 µg/L from the present
analysis. 
Materials and Methods
Patients. From 1992 to 1998 blood levels
of PCP, PCBs, HCHs, and HCB were
determined in 146 patients. Immune para-
meters were measured in 141 individuals.
Two patients were investigated in 1992, 2 in
1993, 6 in 1994, 10 in 1995, 30 in 1996, 44
in 1997, and 52 in 1998. We studied 12
patients at least twice during a mean time
interval of 936 days. In these patients, only
the results of the last determination were
used for statistical analysis. The patients had
various clinical symptoms: 82% of the
patients complained about a lack of mental
concentration, 80% about rapid exhaustion,
50% had frequent common cold diseases,
39% had bronchitis, 14% experienced
sleeplessness, 8% had irritations of mucous
membranes of the throat and nose, 7%
complained about general fatigue, and 2%
about nausea. These clinical symptoms are
in accordance with other reports of PCP-
(50,51) and PCB-exposed patients (52,53).
As determined by a questionnaire, 144 of
146 patients in the study were nonsmokers
at the time of the investigation because they
tried to avoid any contact with pollutants.
The mean (± 1 SD) age of the patients was
46.8 ± 12.5 years (range, 8.6–74.2 years; ≤
18 years, n = 3; ≤ 30 years, n = 9; ≤ 40
years, n = 36; ≤ 50 years, n = 87; ≤ 60 years,
n = 124); 71 were male and 75 were female.
Patients with chronic diseases such as
hepatitis B virus infection, renal failure, dia-
betes mellitus, or rheumatism were excluded
from the study. The patients were occupa-
tionally exposed to PCBs for more than 6
months. Most of them were teachers, con-
struction workers, or telecommunication
technicians who were exposed to PCBs in
schools, building sites, or factories. Ninety
percent of the patients were exposed to
PCBs for more than 20 years. Half of the
patients were still exposed at the time of
investigation. We did not determine blood
levels of chemicals in controls.
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Articles
Pentachlorophenol (PCP), hexachlorocyclohexane-α , -β , and -γ (HCH-α , -β , and -γ ), polychlori-
nated biphenyls (PCBs), and hexachlorobenzene (HCB) are widely distributed industrial chemi-
cals. They are suspected to induce immunologic impairments in exposed individuals. We
examined dose–response relationships of blood levels of these chemicals with cellular (numbers of
lymphocyte subpopulations, in vitro lymphocyte response) or humoral (plasma cytokine levels,
immunoglobulin autoantibodies) immunologic dysfunctions. We studied 146 patients who had
been occupationally exposed primarily to PCBs for more than 6 months. Lymphocyte subpopula-
tions, in vitro responses to mitogens and allogeneic stimulator cells, plasma neopterin, cytokines,
soluble cytokine receptors, soluble adhesion molecules, anti-Ig autoantibodies, and liver transami-
nases were determined. Blood levels of the different compounds were strongly correlated with one
another. There were only weak dose–response relationships between blood levels of PCBs with
cellular immune parameters, and of HCHs and HCB with humoral immune parameters. An
exception was the statistically signiﬁcant negative association of HCB with interferon-γ ( IFN-γ) ,
indicating that HCB has a signiﬁcant impact on Th1 lymphocytes. Patients with HCB blood lev-
els above the mean of 1,109 ng/L more often had undetectable IFN-γ blood levels than patients
below the mean. Patients with increased PCB 138 (> 710 ng/L) had more frequently unde-
tectable interleukin-4 blood levels than patients with PCB 138 below the mean, and patients with
increased PCB 101 (> 31 ng/L) more often had low DR+ cell counts in the blood (< 190/µL)
than patients with PCB 101 below the mean. To assess possible cumulative effects, we compared
patients who had blood levels of all compounds below background with patients who had blood
levels of all compounds above background. Patients with low or absent blood levels of the com-
pounds studied had higher IFN-γ plasma levels, providing some evidence for a cumulative effect
of several weakly active compounds. In conclusion, exposure to PCBs, HCB, or HCHs is associ-
ated with weak immunologic abnormalities. These results contrast with those obtained in earlier
studies of blood levels of PCP, which showed a strong dose-dependent relationship with
immunologic impairments. Our data suggest that long-term exposure of patients to HCB sup-
presses IFN-γ production. Key words: cytokines, hexachlorobenzene, hexachlorocyclohexane,
immune function, lymphocytes, polychlorinated biphenyls. Environ Health Perspect 109:173–178
(2001). [Online 25 January 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p173-178daniel/abstract.htmlDetermination of plasma cytokines, solu-
ble cytokine receptors, soluble cytokine receptor
antagonists, and soluble adhesion molecules.
Values obtained in 40 healthy controls are
given in Table 1. Interleukin (IL)-1α , IL-1β ,
soluble interleukin receptor antagonist (sIL-
[1]RA), IL-2, IL-3, IL-4, IL-6, sIL-6R, IL-8,
transforming growth factor (TGF)-β 2, and
tumor necrosis factor (TNF)-α were mea-
sured by ELISA using Quantikine kits (R&D
Systems, Firma Biermann, Bad Nauheim,
Germany), soluble intercellular adhesion
molecule (sICAM)-1 with Cellfree kits (T
Cell Diagnostics, Biermann), sIL-2R with
Immunotech kits (Dianova, Hamburg,
Germany), interferon (IFN)-γ with HBT kits
(Holland Biotechnology BV, Biermann), and
IL-10 with Cytoscreen kits (Laboserv,
Giessen, Germany). Plasma was snap frozen
within 2 hr after blood was drawn and stored
at –30°C until testing. 
Determination of lymphocyte subpopula-
tions. Lymphocyte subpopulations were
determined as described previously (38). The
mean ± 1 SD of the absolute lymphocyte
count in 40 healthy controls was 1,804 ±
576/µL. Other values are given in Table 1.
The following panel of antibodies was used:
CD3 (OKT3, pan T lymphocytes); CD4
(OKT4, helper/inducer T lymphocyte sub-
set); CD8 (suppressor/cytotoxic T lympho-
cyte subset); OK-DR (MHC class II positive
T and B lymphocytes, monocytes); CD25
(OKT26a, IL-2 receptor positive T lympho-
cytes); CD16 [OK-NK, natural killer (NK)
cells]; CD19 (OKB19, B lymphocytes);
CD11b (OKM1, monocytes, granulocytes,
NK cells); and CD56 (NK cell subset), all
from Ortho (Raritan, NJ, USA). Ten micro-
liters of mononuclear antibody were added
to 100 µL of whole blood and incubated for
30 min at 4°C. Erythrocytes were lysed with
NH4Cl. The cells were washed and incu-
bated with 50 µL ﬂuorescein isothyocyanate-
conjugated goat–anti-mouse Ig (Medac,
Hamburg, Germany) for another 30 min at
4°C, washed again, and analyzed with an
Ortho Cytoron flow cytometer using the
same lymphocyte window for all patients.
CD8+/CD56+ NK cell subsets were deter-
mined using double fluorescence flow
cytometry with a FACScan flow cytometer
(Becton Dickinson, Sunnyvale, CA, USA).
The mean ± 1 SD range of the CD4/CD8
ratio was 2.0 ± 0.6. 
Mitogen stimulation and mixed lympho-
cyte culture. Mononuclear cells obtained from
heparinized blood were adjusted to 1 × 106
cells/mL in culture medium TC-199 (Gibco,
Grand Island, NY, USA) containing 20%
heat-inactivated human AB-serum, 20 mM/L
HEPES buffer, 100 U/mL penicillin, and 100
µg/mL streptomycin. We tested in vitro
stimulation of lymphocytes using pokeweed
mitogen (PWM; Gibco, Paisley, Scotland),
concanavalin A (Con A; Pharmacia, Uppsala,
Sweden), phytohemagglutinin (PHA;
Wellcome, Dartford, UK), or OKT3 mAb
(anti-CD3; Ortho) in three different concen-
trations. We assessed the mixed lymphocyte
culture (MLC) response using allogeneic
MHC-incompatible stimulator cells pooled
from three healthy donors. We added 100 µL
of irradiated pooled allogeneic stimulator cells
(106 cells/mL) to wells of a microtray. All cul-
tures were performed in triplicate by standard
methods. Mitogen stimulation assays were
incubated at 37°C for 3 days and MLCs for 6
days. The cultures were pulsed with 20 µL
3H-thymidine (1 mCi/mL), harvested after an
additional 16 hr, and the incorporation of
3H-thymidine was measured. We calculated
relative reponses (RR) as counts per minute of
patient lymphocytes cultured with mitogen
minus counts per minute of patient lympho-
cytes in medium, divided by counts per
minute of control lymphocytes cultured with
mitogen minus counts per minute of control
lymphocytes in medium. The maximum RR
of each mitogen was used for statistical analy-
sis. Based on control measurements in 52
healthy individuals, an RR < 0.5 was consid-
ered abnormally low. 
Determination of plasma neopterin.
Plasma neopterin was measured initially
with the neopterin-RIAcid assay and since
1995 with the Neopterin ELISA (Brahms,
Berlin, Germany). Based on control mea-
surements in 70 healthy individuals, we con-
sidered > 15 nmol/L abnormally high for
both tests (54).
Enzyme immunoassay for determination
of anti-Ig activities. Anti-Ig autoantibodies
were determined as previously described
(54). We coated 96-well microtiter plates
(Nunc, Roskilde, Denmark) at 37°C for 16
hr with either 0.5 µg/well of human IgG-
Fab (ICN Biochemicals, Costa Mesa, CA,
USA) or IgG-F(ab´)2 fragments (Dianova).
Uncoated sites were blocked for 3 hr at 37°C
with 1% phosphate-buffered saline–bovine
serum albumin.
To determine IgG–anti-Fab and
IgG–anti-F(ab´)2 activities, 50 µL of 1:64
diluted test serum was added; to determine
IgA–anti-Fab and IgA–anti-F(ab´)2 activities,
50 mL of 1:32 diluted test serum was added;
and to determine IgM–anti-Fab and
IgM–anti-F(ab´)2 activities, 50 mL of 1:16
diluted test serum was added to the Fab- or
F(ab´)2-coated wells in the ﬁrst step. In the
second step, the reaction was developed with
50 µL of alkaline phosphatase-conjugated
goat antibodies speciﬁc for the Fc fragments
of IgG, IgA, or IgM molecules (Dianova;
working dilutions 1:5000). In all assays
phosphate-buffered saline-Tween 0.05% was
used as washing buffer and p-nitrophenyl
phosphate disodium solution (Sigma
Chemical Co., St. Louis, MO, USA) as sub-
strate. All incubation steps with test sera and
antibodies were performed at 22°C for 1 hr.
After each step the plates were washed four
times with washing buffer. The optical den-
sity (OD) was measured (± SEM) at 405 nm
using a 340 ATTC Microplate Reader (SLT,
Crailsheim, Germany).
Determination of PCP, PCBs, HCB,
and HCHs in blood. Blood levels of PCP,
PCBs, HCB, and HCHs were determined in
the laboratory of K. Bauer (Saarbrücken,
Germany) using gas chromatography
(Hewlett Packard-GC 5890; Hewlett
Packard, Palo Alto, CA, USA). Reference
blood levels were determined by calculating
the 95% quantile in 2941 randomly selected
individuals who did not have a history of
exposure to the chemicals.
Statistical analysis. Spearman rank corre-
lation, Wilcoxon signed-rank test, and
Fisher’s exact test were applied using SPSS
(Chicago, IL, USA). Adjustment for multiple
testing was done according to the method of
Bonferroni. 
Results
Most patients were exposed to several of the
investigated chemicals as indicated by
increased blood levels of these chemicals
above background (Table 2). Background
blood levels were determined by calculating
the 95% quantile in 2,941 randomly selected
individuals who did not have a history of
exposure to the chemicals. Means and ranges
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Table 1. Mean values for studied parameters in
control subjects.
Parameter Mean ± SD
IL-1α 0 ± 0 pg/mL
IL-1β 0 ± 1 pg/mL
sIL-1RA 670 ± 1,164 pg/mL
IL-2 24 ± 38 pg/mL
sIL-2R 2,085 ± 2,126 pg/mL
IL-3 27 ± 50 pg/mL
IL-4 6 ± 17 pg/mL
IL-6 2 ± 12 pg/mL
sIL-6R 28,212 ± 7,836 pg/mL
IL-8 51 ± 128 pg/mL
IL-10 0 ± 1 pg/mL
TGF-β 2 4 ± 7 pg/mL
IFN-γ 383 ± 859 ng/mL
sICAM-1 263 ± 173 pg/mL
TNF-α 12 ± 55 pg/mL
CD3 1,380 ± 432 µL
CD4 837 ± 297/µL
CD8 451 ± 176/µL
OK-DR 317 ± 127/µL
CD25 119± 57/µL
CD16 183 ± 110/µL
CD19 228 ± 118/µL
CD11b 216 ± 176/µL
CD8+/CD56+ NK subset 134 ± 113/µL
Abbreviations: IFN, interferon; IL, interleukin; sICAM-1,
soluble intercellular adhesion molecule 1; sIL, soluble
IL-1 receptor antagonist; TGF-β 2, transforming growth
factor β 2; TNF-α , tumor necrosis factor α .Articles • PCB, HCH, HCB blood levels and immune function
of PCB 101, PCB 138, PCB 153, PCB 180,
HCH-β , HCH-γ , and HCB blood levels in
patients with PCP blood levels ≤ 10 µg/L are
shown in Table 2. The blood levels of many
compounds were correlated with one another,
indicating multiple exposure (Table 3). 
We found only weak dose–response rela-
tionships between blood levels of PCBs,
HCHs, or HCB with cellular and humoral
immune parameters (Table 4). PCBs were
weakly associated with in vitro lymphocyte
stimulation and the numbers of lymphocyte
subpopulations in the blood, as well as titers
of different autoantibody types against
immunoglobulin components, whereas
HCH-β (Spearman rank correlation, vs. IL-
2: r = 0.182, p = 0.040; vs. IL-10: r = 0.190;
p = 0.032), HCH-γ (Spearman rank correla-
tion, vs. IL-1β : r = –0.336, p = 0.024), and
HCB (Spearman rank correlation, vs. IL-6: r
= –0.189, p = 0.036; vs. sIL-1RA: r = 0.197,
p = 0.029) were weakly associated with
plasma levels of cytokines and cytokine
receptor antagonists. The most prominent
finding was a strong negative association
between HCB and IFN-γ blood levels
(Spearman rank correlation: r = –0.357, p <
0.0001), indicating that HCB has a signiﬁ-
cant impact on Th1 lymphocytes (Table 4). 
When we calculated the frequency of
individuals with impaired (below the mean
–1 SD level) immune parameters in relation
to blood levels above the mean, there were
few associations that remained significant
after adjustment for multiple testing (n = 38
analyzed parameters). Patients with HCB
blood levels above the mean of 1,109 ng/L
more often had undetectable IFN-γ  blood
levels than patients below the mean (23/52
vs. 11/72; Fisher’s exact test: p = 0.0005).
Patients with increased PCB 138 (> 710
ng/L) more frequently had undetectable IL-
4 blood levels than patients with PCB 138
below the mean (29/47 vs. 23/78; Fisher’s
exact test: p = 0.0007), and patients with
increased PCB 101 (> 31 ng/L) more often
had low DR+ cell counts in the blood
(< 190/µL) than patients with PCB 101
below the mean (12/50 vs. 2/81; Fisher’s
exact test: p = 0.0002).
To assess possible cumulative effects, we
compared patients who had blood levels of all
compounds below background with patients
who had blood levels of all compounds above
background. Patients with low or absent
blood levels of the chemicals studied had
higher T lymphocyte counts (CD3/µL:
1,772 ± 606 vs. 1,297 ± 496; p = 0.051),
higher IFN-γ plasma levels (IFN-γ : 638 ±
737 pg/mL vs. 178 ± 313 pg/mL; p = 0.016),
and lower GGT plasma levels (γ -glutamyl
transpeptidase; 8 ± 2 U/mL vs. 15 ± 9 U/mL;
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Table 2. Number and percentage of patients with PCB, HCB, or HCH blood levels above background.
No. of patients with 
blood level above
Background level  background (%) Mean 5% Quantile of 95% Quantile of
of chemical (ng/L)a (n = 141) blood level blood level blood level
PCB 28 < 10 1 (1)
PCB 52 < 10 1 (1)
PCB 101 < 100 0 31.4 13.0 66.0
PCB 138 < 500 98 (70) 710.1 269.0 1444.0
PCB 153 < 600 111 (79) 1025.1 389.0 2221.0
PCB 180 < 300 107 (76) 599.1 141.0 1066.0
HCB < 1,000 60 (43) 1109.4 228.7 2973.7
HCH-α <10 0 < 10
HCH-β <350 13 (9) 256.2 101.0 513.5
HCH-γ <70 6 (4) 26.9 11.0 54.9
All patients analyzed had a PCP blood level < 10 µg/L.
aThe 95% quantile was defined in 2,941 randomly selected individuals who did not have a history of exposure to the
chemical.
Table 3. Cross-associations (Spearman rank correlations; r) of PCB 101, PCB 138, PCB 153, PCB 180, HCB,
PCP, HCH-β , and HCH-γ blood levels in 141 patients. 
PCB 101 PCB 138 PCB 153 PCB 180 HCB PCP HCH-γ
PCB 138 0.247**
PCB 153 0.183* 0.959##
PCB 180 0.201* 0.827## 0.828##
HCB 0.103 0.506## 0.473## 0.334##
PCP 0.166 0.082 0.079 0.051 0.315##
HCH-β 0.009 0.471## 0.454## 0.347## 0.543## 0.003
HCH-γ –0.039 –0.008 0.007 0.004 0.064 0.154 0.152
All patients analyzed had a PCP blood level < 10 µg/L.
*p < 0.05; **p < 0.01; ##p < 0.0001.
Table 4. Association (Spearman rank correlations) of PCB 101, PCB 138, PCB 153, PCB 180, HCB, HCH-β , and HCH-γ plasma levels with numbers of lymphocyte
subpopulations, in vitro lymphocyte response, plasma cytokine levels, and immunoglobulin autoantibodies in 141 patients.
PCB 101 PCB 138 PCB 153 PCB 180 HCB HCH-β HCH-γ
p (r ) p (r ) p (r) p (r) p (r) p (r) p (r)
CD4/CD8 NS NS NS NS NS NS 0.035 (–0.183)
CD4/µL 0.017 (0.208) NS NS NS NS NS NS
CD16/µL NS NS NS 0.049 (0.172) NS NS NS
CD25/µL 0.029 (0.191) 0.043 (–0.177) 0.036 (–0.183) NS NS NS NS
CD8/56/µL 0.023 (–0.495) NS NS NS NS NS NS
CD11b/µL NS NS NS NS NS NS 0.015 (0.366)
PHA (RR) NS NS 0.029 (–0.192) 0.018 (–0.207) NS NS NS
CD3 mab (RR) NS NS 0.047 (–0.176) NS NS NS NS
IL-1β NS NS NS NS NS NS 0.024 (–0.336)
IL-2 NS NS NS NS NS 0.040 (0.182) NS
IL-6 NS NS NS NS 0.036 (–0.189) NS NS
IL-10 NS NS NS NS NS 0.032 (0.190) NS
INF-γ NS NS NS NS 0.0001a (–0.357) NS NS
TGF-β 2 NS 0.039 (0.194) NS 0.035 (0.199) NS NS NS
sIL-1RA NS NS NS NS 0.029 (0.197) NS NS
IgA–anti-Fab NS NS NS 0.021 (0.219) NS NS NS
IgM–anti-Fab NS 0.004 (–0.271) 0.001 (–0.307) 0.004 (–0.272) NS NS NS
IgM–anti-F(ab’)2 NS 0.021 (–0.218) 0.006 (–0.256) 0.041 (–0.193) NS NS NS
GGT (U/mL) NS 0.009 (0.238) 0.017 (0.217) 0.050 (0.179) NS 0.016 (0.218) NS
Abbreviations: GGT, γ -glutamyl transpeptidase; NS, not signiﬁcant. Only p-values < 0.05 are listed. p-Values were calculated using the Spearman rank correlation test. Adjustment for
multiple testing was done according to the method of Bonferroni. All patients analyzed had a PCP blood level of < 10 µg/L. 
aSigniﬁcant (p < 0.05) after adjustment for multiple testing (analyzed parameters; n = 38). p = 0.055), which provides some evidence for
a cumulative effect of several weakly active
compounds (Table 5). 
We studied 12 patients twice during a
mean time interval of 936 days. HCH-γ
blood levels decreased from a mean of 36.3
ng/L to a mean of 19.2 ng/L (p = 0.033),
whereas the mean PCB 153 blood level
increased from 857.0 ng/L to 1024.4 ng/L
(p = 0.050). The blood levels of the other
chemicals were not significantly different
between the two measurements, suggesting
rather constant exposure (Table 6). 
Discussion
PCP, PCBs, HCB, and HCHs are incorpo-
rated into human tissues transdermally or via
inhalation, or they can become part of the
food chain and accumulate in the body,
especially in lipophilic body tissues. During
periods of starvation or after cessation of
exposure, the chemicals are redistributed to
the blood from lipophilic tissues. Long-term,
low-dose exposure is suspected to cause clini-
cal symptoms, such as chronic infections of
the upper respiratory tract, general fatigue,
and neurotoxicity. 
In this study we analyzed individuals
with a documented history of PCB, HCB,
and HCH exposure who had PCP blood
levels in the background range of ≤ 10 µg/L.
Because PCP was shown in previous studies
to be strongly associated with humoral and
cellular dysfunction, we excluded individuals
with PCP blood levels > 10 µg/L from the
analysis (38,49). The blood levels of PCBs,
HCB, and HCHs were often associated with
one another, suggesting simultaneous expo-
sure, making it difficult to dissociate the
impact of individual compounds. The
observed positive and negative associations
of cellular and humoral immune parameters
with blood levels of PCBs, HCB, and HCHs
were relatively weak, with the exception of a
strongly negative association of IFN-γ with
HCB. This ﬁnding indicates that HCB has a
significant impact on Th1 lymphocytes in
vivo. IFN-γ , which is produced by Th1 lym-
phocytes, is involved in the induction of cel-
lular immune responses against antigens
such as viruses by activating NK cells, mono-
cytes/macrophages, and granulocytes, and in
humoral immune responses by increasing
the immunoglobulin secretion of plasma
cells. Impaired IFN-γ production might
favor infections. These data are in agreement
with reports that oral exposure to HCB at
concentrations of 150 and 450 mg/kg food
for 6 weeks suppressed NK activity in rat
lungs in a dose-related manner (56).
Immunotoxic effects of HCB on the patho-
genesis of systemic, pneumonic, and hepatic
viral infections were described in the mouse
(57). Moreover, HCB has been reported to
suppress humoral and cell-mediated immu-
nity to protozoan (malaria and leishmania)
infections and to tumor cell challenges in the
mouse (58). Gram-negative endotoxin
(Salmonella typhosa) sensitivity in PCB- and
HCB-treated mice was increased 5.2- and
32-fold, respectively (59). Mice fed PCB or
HCB for 3–6 weeks and inoculated with
Plasmodium berghei had decreased survival
times (59). Workers exposed to HCB showed
an impaired lytic activity of neutrophils in the
presence of Candida albicans and Candida
pseudotropicalis (60). It is noteworthy that NK
cells seem to have a role in the pathogenesis of
chronic fatigue syndrome (CFS) (61) and that
patients with CFS showed elevated HCB
serum levels (62). The incidence of HCB
contamination (> 2.0 ppb) was 45% in a CFS
group compared with 21% in a non-CFS
control group (p < 0.05) (62). 
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Table 5. Immune and enzymatic parameters (means ± 1 SD) of patients with blood levels of all compounds
below background versus immune and enzymatic parameters of patients with blood levels of all com-
pounds above background.
Patients with blood levels of all compounds
Below background Above background
Parameter (n = 9) (n = 40) p
Lymphocytes/µL 2,357 ± 897 1,868 ± 824 NS
CD3/µL 1,772 ± 648 1,297 ± 502 0.051
CD4/µL 1,120 ± 539 788 ± 323 NS
CD8/µL 537 ± 207 466 ± 250 NS
CD16/µL 259 ± 279 243 ± 143 NS
CD19/µL 305 ± 157 250 ± 234 NS
CD25/µL 128 ± 62 114 ± 113 NS
DR/µL 384 ± 127 360 ± 351 NS
Con A (RR) 1.2 ± 0.9 1.1 ± 0.6 NS
PHA (RR) 2.0 ± 2.9 0.9 ± 0.5 NS
PWM (RR) 1.7 ± 1.8 1.4 ± 1.0 NS
CD3 mab (RR) 7.5 ± 13.7 3.1 ± 6.6 NS
MLC (RR) 2.1 ± 1.6 1.4 ± 2.0 NS
Neopterin (nmol/L) 21 ± 37 8 ± 4 NS
IL-1α (pg/mL) 1 ± 1 1 ± 1 n.s
IL-1β (pg/mL) 1 ± 1 0 NS
sIL-1RA (pg/mL) 431 ± 145 646 ± 704 NS
IL-2 (pg/mL) 10 ± 10 12 ± 11 NS
sIL-2R (pg/mL) 1,919 ± 1,422 2,192 ± 2,021 NS
IL-3 (pg/mL) 68 ± 146 16 ± 26 NS
IL-4 (pg/mL) 87 ± 247 5 ± 11 NS
IL-6 (pg/mL) 216 ± 442 62 ± 112 NS
sIL-6R (pg/mL) 35,781 ± 17,854 30,498 ± 14,369 NS
IL-8 (pg/mL) 49 ± 12 37 ± 43 NS
IL-10 (pg/mL) 3 ± 5 14 ± 48 NS
TNF-α (pg/mL) 41 ± 72 78 ± 245 NS
TGF-β 2 (pg/mL) 2 ± 2 12 ± 20 NS
IFN-γ (pg/mL) 638 ± 737 178 ± 318 0.016
sICAM-1 (µg/mL) 185 ± 42 348 ± 146 NS
SGOT (U/mL) 10 ± 7 10 ± 3 NS
GPT (U/mL) 14 ± 10 14 ± 7 NS
GGT (U/mL) 8 ± 3 15 ± 10 0.055
IgA–anti-Fab (OD) 0.1 ± 0.1 0.2 ± 0.1 NS
IgA–anti-F(ab’)2 (OD) 0.1 ± 0.1 0.2 ± 0.2 NS
IgG–anti-Fab (OD) 0.4 ± 0.4 0.3 ± 0.3 NS
IgG–anti-F(ab’)2 (OD) 0.7 ± 0.4 0.6 ± 0.4 NS
IgM–anti-Fab (OD) 0.2 ± 0.1 0.1 ± 0.1 NS
IgM–anti-F(ab’)2 (OD) 0.1 ± 0.1 0.1 ± 0.1 NS
Abbreviations: GPT, glutamic pyruvic transaminase; NS, not significant; SGOT, serum glutamic–oxaloacetic transami-
nase; sICAM-1, soluble intercellular adhesion molecule 1. All patients analyzed had a PCP blood level < 10 µg/L.
Background levels: PCB 138 < 500 ng/L, PCB 153 < 600 ng/L, PCB 180 < 300 ng/L, HCB < 1,000 ng/L.
Table 6. Blood levels (mean ± 1 SD) of PCB 101, PCB 138, PCB 153, PCB 180, HCB, HCH-β , and HCH-γ in 12
patients who were tested twice (mean time interval, 936 days).
First determination Second determination p
PCB 101 (ng/L) 46.5 ± 26.7 28.9 ± 16.4 0.221
PCB 138 (ng/L) 598.0 ± 160.1 700.5 ± 315.9 0.084
PCB 153 (ng/L) 857.0 ± 261.2 1024.4 ± 518.1 0.050
PCB 180 (ng/L)  437.0 ± 191.5 474.0 ± 296.9 0.610
HCB (ng/L) 1240.8 ± 1150.4 879.4 ± 461.9 0.155
HCH-β (ng/L) 188.0 ± 66.4 186.0 ± 58.6 0.625
HCH-γ (ng/L) 36.3 ± 25.6 19.2 ± 9.2 0.033
p-Values were calculated using the Wilcoxon signed-ranks test. All patients analyzed had a PCP blood level < 10 µg/L.The impact of HCB on humoral
immune responses is controversial, especially
concerning autoimmune responses. Our
ﬁnding of a positive association of IgA–anti-
Fab serum autoantibodies and the lack of an
association of IgG–anti-Fab and IgG–anti-
F(ab´)2 with HCB blood levels are in partial
agreement with observations describing dose-
dependent increases of serum levels of IgM,
IgA, and autoantigen-speciﬁc IgM as well as
unchanged levels of IgG and IgG autoanti-
body levels in rats given HCB in their diet
(13,63). The negative associations of
IgM–anti-Fab and IgM–anti-F(ab´)2 with
PCBs in our patients vary with findings in
animals on IgM responses against single-
stranded DNA, native DNA, rat IgG
(representing rheumatoid factor), and brome-
lain-treated mouse erythrocytes (13).
However, others reported that antibody syn-
thesis to sheep red blood cells was signifi-
cantly depressed in PCB- and HCB-treated
mice, and serum IgA concentrations were
consistently 40–80 mg/dL lower than con-
trols (59). The ability of HCB to elevate
serum antibody levels against autoantigens
but not against foreign antigens suggests that
HCB does not act as a polyclonal B cell acti-
vator (13). HCB activates rat splenic B-1
cells committed to produce autoantibodies
associated with systemic autoimmune dis-
eases (13,64). It is of interest that increased
IgG and IgM serum levels were reported in
HCB-exposed workers (65). However, the
workers were not examined for the presence
of autoimmune phenomena.
The weak associations of PCBs, HCB,
and HCHs with immunologic abnormalities
described herein are in stark contrast to the
striking abnormalities observed in individuals
with high blood levels of PCP (38,49). The
clinical relevance of HCB-associated suppres-
sion of IFN-γ awaits further clariﬁcation. 
REFERENCES AND NOTES
1. Cleseri LS. Case history: PCBs in the Hudson River. In:
Introduction to Environmental Toxicology (Guthrie FE,
Perry JJ, eds). New York:Elsevier/North Holland,
1980;227–235. 
2. Fishbein L. Toxicity of chlorinated biphenyls. Annu Rev
Pharmacol 14:139–156 (1974). 
3. Kimbrough R. Human health effects of PCBs and PBBs.
Annu Rev Pharmacol Toxicol 27:87–111 (1987).
4. Pott F, Krooß J, Köhler M, Stolz P. Bremer Umweltinstitut.
In: Gift im Holz. Reihe: Umwelt & Arbeit. Bremen,
Germany:Bremer Umweltinstitut e. V., 1994;33.
5. Zheng T, Holford TR, Mayne ST, Tessari J, Owens PH,
Zahm SH, Zhang B, Dubrow R, Ward B, Carter D, et al.
Environmental exposure to hexachlorobenzene (HCB)
and risk of female breast cancer in Connecticut. Cancer
Epidemiol Biomark Prev 8:407–411 (1999). 
6. Svensson B-G, Hallberg T, Nilsson A, Schütz A, Hagmar
L. Parameter of immunological competence in subjects
with high consumption of ﬁsh contaminated with persis-
tent organochlorine compounds. Int Arch Occup Environ
Health 65:351–358 (1994).
7. Nelson N. Polychlorinated biphenyls: environmental
impact. Environ Res 5:253–362 (1972).
8. Zitco V, Choi PMK. PCB and Other Industrial Halogenated
Hydrocarbons in the Environment. Fisheries Research
Board of Canada, Technical Report 272. St. Andrews,
New Brunswick, Canada:Biological Station, Fisheries
Research Board of Canada, 1971;2–54. 
9. Higuchi K, ed. PCB Poisoning and Pollution. New
York:Academic Press, 1976.
10. Buckley JL, ed. National Conference on Polychlorinated
Biphenyls. Washington DC:U.S. Environmental Protection
Agency, 1976.
11. Yoo BS, Jung KH, Hana SB, Kim HM. Apoptosis-medi-
ated immunotoxicity of polychlorinated biphenyls (PCBs)
in murine splenocytes. Toxicol Lett 91:83–89 (1997).
12. Hoffman DJ, Melancon MJ, Klein PN, Rice CP, Eisemann
JD, Hines RK, Spann JW, Pendleton GW. Developmental
toxicity of PCB 126 (3,3’,4,4’,5-pentachlorobiphenyl) in
nestling American kestrels (Falco sparverius). Fundam
Appl Toxicol 34:188–200 (1996). 
13. Schielen P, Van Der Pijl A, Bleumink R, Pieters RH, Seinen
W. Local popliteal lymph node reactions to hexa-
chlorobenzene and pentachlorobenzene: comparison with
systemic effects. Immunopharmacology 31:171–181 (1996).
14. De Swart RL, Ross PS, Vos JG, Osterhaus AD. Impaired
immunity in harbour seals (Phoca vitulina) fed environmen-
tally contaminated herring. Vet Q(suppl 3):S127–128 (1996).
15. Ross PS, Van Loveren H, De Swart RL, van der Vliet H, de
Klerk A, Timmermann HH, van Binnendijk R, Brouwer A,
Vos JG, Osterhaus AD. Host resistance to rat
cytomegalovirus (RCMV) and immune function in adult
rats fed herring from contaminated Baltic Sea. Arch
Toxicol 70:661–671 (1996).
16. Arnold DL, Bryce F, McGuire PF, Stapley R, Tanner JR,
Wrenshall E, Mes J, Fernie S, Tryphonas H, Hayward S,
et al. Toxicological consequences of aroclor 1254 inges-
tion by female rhesus (Macaca mulatta) monkeys. Part 2.
Reproduction and infant finding. Food Chem Toxicol
33:457–474 (1995).
17. Nakanishi Y, Nomoto Y, Matsuki A, Kunitake R, Hara N.
Effect of polychlorinated biphenyls and polychlorinated
dibenzofurans on leukocyte in peripheral blood and
bronchoalveolar lavage fluid. Fukuoka Igaku Zasshi
86:261–266 (1995).
18. Lahvis GP, Wells RS, Kuehl DW, Stewart JL, Rhinehart
HL, Via CS. Decreased lymphocyte responses in free-
ranging bottlenose dolphins (Tursiops truncatus) are
associated with increased concentrations of PCBs and
DDT in peripheral blood. Environ Health Perspect
103(suppl 4):67–72 (1995).
19. De Krey GK, Baecher-Steppan L, Fowles JR, Kerkvliet NI.
Polychlorinated biphenyl-induced suppression of cyto-
toxic T lymphocyte activity: role of prostaglandin-E2.
Toxicol Lett 74:211–220 (1994).
20. Lai ZW, Kremer J, Gleichmann E, Esser C. 3,3’,4,4’-tetra-
chlorobiphenyl inhibits proliferation of immature thymo-
cytes in fetal thymus organ culture. Scand J Immunol
39:480–488 (1994).
21. Arkoosh MR, Clemons E, Myers M, Casillas E. Suppression
of B-cell mediated immunity in juvenile chinook salmon
(Oncorhynchus tshawytscha) after exposure to either a
polycyclic aromatic hydrocarbon or to polychlorinated
biphenyls. Immunopharmacol Immunotoxicol 16:293–314
(1994).
22. De Krey GK, Hollingshead NC, Kerkvliet NI, Smith BB.
Suppression of prolactin and cytotoxic T-lymphocyte
activity in PCB-treated mice. Int J Immunopharmacol
16:251–257 (1994).
23. Harper N, Howie L, Connor K, Dickerson R, Safe S.
Immunosuppressive effects of highly chlorinated biphenyls
and diphenyl ethers on T-cell dependent and independent
antigens in mice. Toxicology 85:123–135 (1993).
24. Esser C, Welzel M. Ontogenic development of murine
fetal thymocytes is accelerated by 3,3’,4,4’-tetrachloro-
biphenyl. Int J Immunopharmacol 15:841–852 (1993).
25. De Krey GK, Baecher-Steppan L, Deyo JA, Smith B,
Kerkvliet NI. Polychlorinated biphenyl-induced immune
suppression: castration, but not adrenalectomy or RU
38486 treatment, partially restores the suppressed cyto-
toxic T lymphocyte response to alloantigen. J Pharmacol
Exp Ther 267:308–315 (1993).
26. Harper N, Connor K, Safe S. Immunotoxic potencies of
polychlorinated biphenyl (PCB), dibenzofuran (PCDF) and
dibenzo-p-dioxin (PCDD) congeners in C57BL/6 and
DBA/2 mice. Toxicology 80:217–227 (1993).
27. Tryphonas H, Luster MI, White KL Jr, Naylor PH, Erdos
MR, Burleson GR, Germolec D, Hodgen M, Hayward S,
Arnold DL. Effect of PCB (Aroclor 1254) on non-specific
immune parameters in rhesus (Macaca mulatta) monkeys.
Int J Immunopharmacol 13:639–648 (1991).
28. Kerkvliet NI, Baecher-Steppan L, Smith BB, Youngberg JA,
Henderson MC, Buhler DR. Role of the Ah locus in sup-
pression of cytotoxic T lymphocyte activity by halogenated
aromatic hydrocarbons (PCBs and TCDD): structure-activ-
ity relationship and effects in C57Bl/6 mice congenic at the
Ah locus. Fundam Appl Toxicol 14:532–541 (1990).
29. Meera P, Rao PR, Shanker R, Tripanthi O. Immuno-
modulatory effects of gamma-HCH (lindane) in mice.
Immunopharmacol Immunotoxicol 14:261–282 (1992).
30. Mandal A, Chakrabort S, Lahiri P. Hematological changes
produced by lindane (gamma-HCH) in six species of
birds. Toxicology 40:103–111 (1986).
31. Das SN, Paul BN, Saxena AK, Ray PK. Effect of in utero
exposure to hexachlorocyclohexane on the developing
immune system of mice. Immunopharmacol Immunotoxicol
12:293–310 (1990).
32. Lang D, Mueller-Ruchholtz W. Human lymphocyte reac-
tivity after in vitro exposure to technical and analytical
grade pentachlorophenol. Toxicology 70:271–282 (1991).
33. Kerkvliet NI, Brauner JA, Matlock JP. Humoral immunotox-
icity of polychlorinated diphenyl ethers, phenoxyphenols,
dioxins and furans present as contaminants of technical
grade pentachlorophenol. Toxicology 36:307–324 (1985).
34. Kerkvliet NI, Brauner JA, Baecher-Steppan L. Effects of
dietary technical pentachlorophenol exposure on T cell,
macrophage and natural killer cell activity in C57Bl/6
mice. Int J Immunopharmacol 7:239–247 (1985).
35. Exon JH, Koller LD. Effects of chlorinated phenols on
immunity in rats. Int J Immunpharmacol 5:131–136 (1983).
36. Blakely BR, Yole MJ, Brousseau P, Boermans H, Fournier
M. Effect of pentachlorophenol on immune function.
Toxicology 125:141–148 (1998).
37. McConnachie PR, Zahalsky AC. Immunological conse-
quences of exposure to pentachlorophenol. Arch Environ
Health 46:249–253 (1991).
38. Daniel V, Huber W, Bauer K, Opelz G. Impaired in-vitro
lymphocyte responses in patients with elevated pen-
tachlorophenol (PCP) blood levels. Arch Environ Health
50:287–292 (1995).
39. Omara FO, Flipo D, Brochu C, Denizeau F, Brousseau P,
Potworowski EP, Fournier M. Lack of suppressive effects
of mixtures containing low levels of methylmercury
(MeHg), polychlorinated dibenzo-p-dioxins (PCDDS),
polychlorinated dibenzofurans (PCDFS), and aroclor
biphenyls (PCBS) on mixed lymphocyte reaction, phago-
cytic, and natural killer cell activities of rat leukocytes in
vitro. J Toxicol Environ Health 54:561–577 (1998).
40. Fowles JR, Fairbrother A, Trust KA, Kerkvliet NI. Effects
of Aroclor 1254 on the thyroid gland, immune function,
and hepatic cytochrome P450 activity in mallards.
Environ Res 75:119–129 (1997).
41. Fernlof G, Gadhasson I, Pora K, Darnerud PO, Thuvander,
A. Lack of effects of some individual polybrominated
diphenyl ether (PBDE) and polychlorinated biphenyl
(PCB) congeners on human lymphocyte functions in
vitro. Toxicol Lett 90:189–197 (1997).
42. Belpaeme K, Delbeke K, Zhu L, Kirsch-Volders M. PCBs
do not induce DNA breakage in vitro in human lympho-
cytes. Mutagenesis 11:383–389 (1996).
43. Lai ZW, Griem P, Gleichmann E, Esser C. CD8 thymocytes
derived from 3,3’,4,4’-tetrachlorobiphenyl-exposed fetal
thymi possess killing activity. Toxicol Appl Pharmacol
133:223–232 (1995).
44. Yu ML, Hsin JW, Hsu CC, Chan WC, Gu YL. The immuno-
logic evaluation of the Yucheng children. Chemosphere
37:1855–1865 (1998).
45. Nagayama J, Tsuji H, Iida T, Hirakawa H, Matsueda T,
Okamura K, Hasegawa M, Sato K, Ma HY, Yanagawa T,
et al. Postnatal exposure to chlorinated dioxins and
related chemicals on lymphocyte subsets in Japanese
breast-fed infants. Chemosphere 37:1781–1787 (1998).
46. Weisglas-Kuperus N, Sas TC, Koopman-Esseboom C, van
der Zwan CW, De Ridder MA, Beishuizen A, Hooijkaas H,
Sauer PJ. Immunologic effects of background prenatal
and postnatal exposure to dioxins and polychlorinated
biphenyls in Dutch infants. Pediatr Res 38:404–410 (1995).
47. Svensson BG, Hallberg T, Nilsson A, Schutz A, Hagmar L.
Parameters of immunological competence in subjects
with high consumption of ﬁsh contaminated with persis-
tent organochlorine compounds. Int Arch Occup Environ
Health 65:351–358 (1994).
Articles • PCB, HCH, HCB blood levels and immune function
Environmental Health Perspectives • VOLUME 109 | NUMBER 2 | February 2001 17748. Lee T-P. The toxic effect of polychlorinated biphenyls. In:
Principles and Practice of Immunotoxicology (Miller K,
Turk JL, Nicklin S, eds). Oxford, UK:Blackwell Scientific
Publications, 1992;242–250.
49. Daniel V, Huber W, Bauer K, Suesal C, Mytilineos J, Melk
A, Conradt C, Opelz G. Association of elevated pen-
tachlorophenol (PCP) blood levels with cellular and
humoral immunodeficiencies. Arch Environ Health (in
press).
50. Ohnsorge P. Is it appropriate to consider wood preserva-
tive poisoning in the differential diagnosis of chronic recur-
rent respiratory tract infections? Laryngorhinootologie
5:131–136 (1991).
51. Rodriguez-Pichardo A, Camacho F, Rappe C, Hansson M,
Smith AG, Greig JB. Chloracne caused by ingestion of
olive oil contaminated with PCDDs and PCDFs. Hum Exp
Toxicol 10:311–322 (1991).
52. Rogan WJ, Gladen BC. Neurotoxicology of PCBs and
related compounds. Neurotoxicology 13:27–35 (1992). 
53. Nakagawa R, Takahashi K. Studies on the application of
residual PCBs, PCQs and PCDFs concentrations to Yusho
diagnosis. Fukuoka Igaku Zasshi 82:280–294 (1991). 
54. Schäfer AJ, Daniel V, Dreikorn K, Opelz G. Assessment of
plasma neopterin in clinical kidney transplantation.
Transplantation 41:454–459 (1986). 
55. Süsal C, Lewin IV, Stanworth DR, Terness P, Daniel V,
Oberg HH, Huth-Kühne A, Zimmermann R, Opelz G. Anti-
IgG autoantibodies in HIV-infected hemophilia patients.
Vox Sang 62:224–229 (1992).
56. Van Loveren H, Krajnc EI, Rombout PJ, Blommaert FA,
Vos JG. Effects of ozone, hexachlorobenzene, and
bis(tri-n-butyltin)oxide on natural killer activity in the rat
lung. Toxicol Appl Pharmacol 102:21–33 (1990).
57. Carthew P, Edwards RE, Smith AG. Immunotoxic effects
of hexachlorobenzene on the pathogenesis of systemic,
pneumonic and hepatic virus infections in the mouse.
Hum Exp Toxicol 9:403–411 (1990). 
58. Vos JG. Immunotoxicity of hexachlorobenzene. IARC Sci
Publ 77:347–356 (1986).
59. Loose LD, Pittman KA, Benitz KF, Silkworth JB, Mueller
W, Coulston F. Environmental chemical-induced immune
dysfunction. Ecotoxicol Environ Saf 2:173–198 (1978).
60. Queiroz ML, Quadros MR, Valadares MC, Silveira JP.
Polymorphonuclear phagocytosis and killing in workers
occupationally exposed to hexachlorobenzene.
Immunopharmacol Immunotoxicol 20:447–454 (1998). 
61. Whiteside TL, Friberg D. Natural killer cells and natural
killer cell activity in chronic fatigue syndrome. Am Med
105(3A):27S–34S (1998). 
62. Dunstan RH, Donohoe M, Taylor W, Roberts TK, Murdoch
RN, Watkins JA, McGregor NR. A preliminary investiga-
tion of chlorinated hydrocarbons and chronic fatigue syn-
drome. Med J Aust 163:294–297 (1995). 
63. Schielen P, Den Besten C, Vos JG, Van Bladeren PJ,
Seinen W, Bloksm N. Immune effects of hexachloroben-
zene in the rat: role of metabolism in a 13-week feeding
study. Toxicol Appl Pharmacol 131:37–43 (1995). 
64. Schielen P, Van Rodijnen W, Pieters RH, Seinen W.
Hexachlorobenzene treatment increases the number of
splenic B-1-like cells and serum autoantibody levels in
the rat. Immunology 86:568–574 (1995). 
65. Queiroz ML, Bincoletto C, Perlingeiro RC, Quadros MR,
Souza CA. Immunoglobulin levels in workers exposed to
hexachlorobenzene. Hum Exp Toxicol 3:172–175 (1998). 
Articles • Daniel et al.
178 VOLUME 109 | NUMBER 2 | February 2001 • Environmental Health Perspectives